Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Hyperglycemia Is Associated with Intraventricular Extension Among Patients with Spontaneous Intracerebral Hemorrhage
Cerebrovascular Disease and Interventional Neurology
P6 - Poster Session 6 (5:30 PM-6:30 PM)
6-011

Stress hyperglycemia is a common finding in spontaneous intracerebral hemorrhage that may be associated with poor outcome. Intraventricular extension is also associated with poor prognosis among patients with intracerebral hemorrhage. Whether intraventricular extension is associated with hyperglycemia is currently unknown.

We aimed to evaluate whether elevated serum glucose is associated with intraventricular extension in patients with intracerebral hemorrhage.
Demographic information, risk factors, and laboratory values including admission serum glucose levels were collected from a prospective database of consecutive non-traumatic ICH patients admitted to a single referral center between 2007 to 2018. Hemorrhage volumes were calculated from baseline computed tomography (CT) scans using the ABC/2 formula, and CT scans were reviewed for the presence of intraventricular extension. Serum glucose values on admission were compared between patients with and without intraventricular extension in univariate and multivariate models.
856 patients with spontaneous intracerebral hemorrhage were included in the analysis. The mean age of the cohort was 71±15 years and the proportion of females was 44%. The mean hemorrhage volume was 32.7±40.6 mL, and intraventricular extension occurred in 318 (37%) patients. Among those with intraventricular extension, the average admission glucose was 159.7±74.1 mg/dL compared to 135.5±56.7 mg/dL (p = 0.01) in those without intraventricular hemorrhage. In a multivariable regression model, admission serum glucose (aOR 1.01, 95% CI (1.00–1.01), p < 0.01) was independently associated with intraventricular extension after adjusting for age, sex, hypertension, diabetes, and hemorrhage volume. 

Admission serum glucose is associated with intraventricular extension among patients with spontaneous intracerebral hemorrhage. Such findings may reflect a stress response that occurs due to the presence of blood products within the ventricles. While further studies are needed to further elucidate the pathophysiological basis for this phenomenon, elevated serum glucose may be a reliable peripheral marker for intraventricular extension.

 

Authors/Disclosures
Alvin Das, MD (Beth Israel Deaconess Medical Center)
PRESENTER
Dr. Das has nothing to disclose.
Elizabeth Heistand Elizabeth Heistand has nothing to disclose.
Robert W. Regenhardt, MD, PhD (Massachusetts General Hospital) Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Rapid Medical. Dr. Regenhardt has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Johnson and Bell Trial Lawyers. The institution of Dr. Regenhardt has received research support from National Institutes of Health. The institution of Dr. Regenhardt has received research support from Society of Vascular and Interventional Neurology. The institution of Dr. Regenhardt has received research support from Heitman Foundation.
Corey R. Fehnel, MD, FAAN (Beth Israel Deaconess Medical Center) Dr. Fehnel has received personal compensation in the range of $500-$4,999 for serving as a Consultant for XRHealth. The institution of Dr. Fehnel has received research support from National Institute on Aging .
Jennifer L. Dearborn-Tomazos, MD (Beth Israel Deaconess Medical Center) An immediate family member of Dr. Dearborn-Tomazos has received personal compensation for serving as an employee of PTC Therapeutics. An immediate family member of Dr. Dearborn-Tomazos has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Dr. Dearborn-Tomazos has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Qmetis. An immediate family member of Dr. Dearborn-Tomazos has stock in Alexion Pharmacueticals. The institution of Dr. Dearborn-Tomazos has received research support from BMS.
Vasileios-Arsenios Lioutas, MD (Beth Israel Deaconess Medical Center, Department of Neurology) Dr. Lioutas has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Qmetis. Dr. Lioutas has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mindray. The institution of Dr. Lioutas has received research support from NIH. The institution of Dr. Lioutas has received research support from Alzheimer's Association.
Sandeep Kumar, MD Dr. Kumar has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for CRICO.
Magdy H. Selim, MD, PhD (Beth Israel Deaconess Med. Ctr.) Dr. Selim has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedRhythms Inc..